PEN - PENUMBRA INC ()

PENのニュース

   Penumbra – Consensus Indicates Potential 51.3% Upside  2022/05/06 11:05:08 DirectorsTalk
Penumbra with ticker code (PEN) have now 6 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 280 and 240 and has a mean target at 258.5. With the stocks previous close at 170.88 this indicates there is a potential upside of 51.3%. There is a 50 day moving average of 203.98 and the 200 day moving average is 244.78. The market capitalisation for the company is $5,793m. Find out more information at: https://www.penumbrainc.com [stock_market_widget type="chart" template="basic" color="green" assets="PEN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $8,763m based on the market concensus. Penumbra designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands.
   Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra''s Price Target - Here''s Why  2022/05/04 19:54:20 Benzinga
Penumbra Inc (NYSE: PEN ) reported Q1 sales that beat Street expectations, driven by Vascular upside, and reiterated its 2022 revenue guidance. Wells Fargo lowered the price target to $265 from 321, which is equivalent to a 52.2% upside. At 9.5x (down from 12x as peer group valuation has been compressed) with a 2023 sales estimate of $1.02 billion, PEN shares would trade essentially in line with its peers, analysts write. Q1 revenue of $203.9 million (+21.8% … Full story available on Benzinga.com
   Penumbra''s (PEN) CEO Adam Elsesser on Q1 2022 Results - Earnings Call Transcript  2022/05/04 03:32:03 Seeking Alpha
Penumbra, Inc. (NYSE:NYSE:PEN) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Jee Hamlyn-Harris – Investor Relations Adam Elsesser – Chairman and Chief…
   Penumbra, Inc. Misses Q1 EPS by 6c, Revenues Beat By Investing.com  2022/05/03 21:16:02 Investing.com
Penumbra, Inc. Misses Q1 EPS by 6c, Revenues Beat
   Penumbra, Inc. Reports First Quarter 2022 Financial Results  2022/05/03 20:05:00 PR Newswire
ALAMEDA, Calif., May 3, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2022. Revenue of $203.9 million in the first quarter of 2022, an increase of 20.5%,…
   Penumbra A Little Beaten Down Despite Strong Growth Opportunities  2022/03/01 21:48:05 Seeking Alpha
   Penumbra, Inc. (PEN) CEO Adam Elsesser on Q4 2021 Results - Earnings Call Transcript  2022/02/23 02:33:03 Seeking Alpha
   Penumbra GAAP EPS of -$0.66 misses by $0.30, revenue of $204M beats by $9.71M  2022/02/22 21:12:03 Seeking Alpha
Penumbra press release (PEN): Q4 GAAP EPS of -$0.66 misses by $0.30.Revenue of $204M (+22.2% Y/Y) beats by $9.71M.
   Penumbra, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results  2022/02/22 21:05:00 PR Newswire
ALAMEDA, Calif., Feb. 22, 2022 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2021. Financial Highlights: Revenue of $204.0 million for the
   Penumbra Q4 2021 Earnings Preview (NYSE:PEN)  2022/02/21 22:35:00 Seeking Alpha
Penumbra (NYSE:PEN) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is $0.22 (-47.6% Y/Y) and the consensus
   Penumbra, Inc. (NYSE:PEN) Receives Consensus Recommendation of Buy from Analysts  2021/12/24 10:48:41 Dakota Financial News
Shares of Penumbra, Inc. (NYSE:PEN) have earned an average rating of Buy from the eight research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that []
   Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ...  2021/12/23 17:38:01 GuruFocus
Related Stocks: ARGX , MGNX , CUTR , RNA , FULC , ITOS , TMO , PEN , TNYA , SGHT , AADI , RCOR , PTGX , MDXG , CSTL , AGEN , ABUS , QDEL , TRIL , CHAQ , BCTG , ITMR , RACA ,
   Penumbra, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference  2021/12/22 21:05:00 Business Insider Markets
ALAMEDA, Calif., Dec. 22, 2021 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 40 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.
   State of New Jersey Common Pension Fund D Reduces Position in Penumbra, Inc. (NYSE:PEN)  2021/12/22 09:42:46 Dakota Financial News
State of New Jersey Common Pension Fund D cut its position in shares of Penumbra, Inc. (NYSE:PEN) by 1.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,684 shares of the companys stock after selling 236 shares during the period. State []
   Penumbra (NYSE:PEN) Downgraded by Zacks Investment Research to Sell  2021/12/22 07:24:42 Dakota Financial News
Zacks Investment Research lowered shares of Penumbra (NYSE:PEN) from a hold rating to a sell rating in a research report released on Tuesday, Zacks.com reports. According to Zacks, Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The companys portfolio of products primarily addresses neuro and peripheral vascular medical []

calendar